Trustiva 1100 mg Tablets

Trustiva combines three antiretroviral agents from two different drug classes into one 1100mg tablet, simplifying HIV treatment for many patients. Tenofovir Disoproxil Fumarate (300mg) and Emtricitabine (200mg) are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), while Efavirenz (600mg) is a non-nucleoside reverse transcriptase inhibitor (NNRTI); together they work at different stages of the viral replication process to more effectively suppress HIV-1. This combination approach helps reduce viral load, allowing the immune system to recover and CD4 cell counts to improve over time. Being a single-tablet, once-daily regimen, Trustiva can make it easier for patients to stay consistent with their treatment schedule, which is important for long-term viral suppression. It is typically taken on an empty stomach or with a low-fat meal, often at bedtime, to help minimize certain side effects associated with Efavirenz, such as dizziness or vivid dreams. Regular follow-up with a healthcare provider is recommended to monitor viral load, CD4 counts, and overall organ function during treatment. Many patients using Trustiva achieve durable viral suppression and meaningful improvements in immune health with consistent adherence. As with all antiretroviral therapy, it should be used under the guidance of an experienced healthcare provider as part of a comprehensive HIV care plan.